Consumer News Popular Weight Loss Drugs Could Lower The Risk Of Certain Cancers, Study Finds
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Consumer News Popular Weight Loss Drugs Could Lower The Risk Of Certain Cancers, Study Finds is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
New weight-loss shot shows major fat reduction, but experts urge caution
The weight-loss drug eloralintide shows up to 20% body weight reduction in trial, offering hope for obesity treatment beyond current GLP-1 medications. Read More
Can Antiobesity Medications Reduce the Risk for Cancer?
A meta-analysis found that antiobesity drugs — with the exception of coagonists — did not reduce the risk for overall or site-specific obesity-associated cancers. Read More
Weight-loss drugs: What other conditions are they being used and tested for?
Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer's patients ... Read More
GLP-1 Weight Loss Drugs Tied to Lower Risk of Early Macular Degeneration
Preliminary studies suggest GLP-1s may offer long-term vision protection for people without diabetes, but researchers caution more research is still needed. During a 10-year study, people without ... Read More
Weight loss drugs improve heart health regardless of amount of weight lost: study
Share on Pinterest A new study finds that GLP-1 drugs’ heart health benefits may not be solely due to weight loss. The Good Brigade/Getty Images As the popularity of GLP-1 receptor agonists for weight ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus